P-GLYCOPROTEIN PLAYS A MAJOR ROLE IN THE EFFLUX OF FEXOFENADINE IN THE SMALL INTESTINE AND BLOOD-BRAIN BARRIER, BUT ONLY A LIMITED ROLE IN ITS BILIARY EXCRETION

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Drug Metabolism And Disposition

• Publication date

  2005-07-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1124/DMD.105.004192PMID 15821041
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of fruit juices on the oral bioavailability of fexofenadine in rats.

  2005cited by this paper
• ATP-Dependent Transport of a Novel Thromboxane A2 Receptor Antagonist, [2-(4-Chlorophenylsulfonylaminomethyl)-Indan-5-yl]Acetate (Z-335) and Its Xenobiotic Taurine Conjugate (Z-335-Tau) by Rat Bile Canalicular Membrane Vesicles

  2004influential reference
• Functional Characterization of pH-Sensitive Organic Anion Transporting Polypeptide OATP-B in Human

  2004cited by this paper
• The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.

  2003cited by this paper
• Multiple transport mechanisms involved in the intestinal absorption and first‐pass extraction of fexofenadine

  2003cited by this paper
• Involvement of multiple transport systems in the disposition of an active metabolite of a prodrug-type new quinolone antibiotic, prulifloxacin.

  2003cited by this paper
• P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists.

  2003influential reference
• Fexofenadine Transport in Caco‐2 Cells: Inhibition with Verapamil and Ritonavir

  2002cited by this paper
• Fruit juices inhibit organic anion transporting polypeptide–mediated drug uptake to decrease the oral availability of fexofenadine

  2002influential reference
• Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition.

  2002cited by this paper
• MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.

  2002cited by this paper
• Effect of St John's wort on the pharmacokinetics of fexofenadine

  2002cited by this paper
• The effect of rifampin administration on the disposition of fexofenadine

  2001cited by this paper
• Nuclear Receptor Response Elements Mediate Induction of Intestinal MDR1 by Rifampin*

  2001cited by this paper
• Hepatic Disposition of Fexofenadine: Influence of the Transport Inhibitors Erythromycin and Dibromosulphothalein

  2000influential reference
• Increased drug delivery to the brain by P‐glycoprotein inhibition

  2000cited by this paper
• Both cMOAT/MRP2 and another unknown transporter(s) are responsible for the biliary excretion of glucuronide conjugate of the nonpeptide angiotensin II antagonist, telmisaltan.

  2000cited by this paper
• Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines.

  1999cited by this paper
• OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.

  1999influential reference
• A multidrug resistance transporter from human MCF-7 breast cancer cells.

  1998cited by this paper
• Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats.

  1998cited by this paper
• Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai hyperbilirubinemic rats.

  1996cited by this paper
• Different biliary excretion systems for glucuronide and sulfate of a model compound; study using Eisai hyperbilirubinemic rats.

  1995cited by this paper
• Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.

  1994cited by this paper

• Mechanisms of altered hepatic drug disposition during pregnancy: small molecules

  2025cites this paper
• Interplay of OATP1A/1B/2B1 uptake transporters and ABCB1 and ABCG2 efflux transporters in the handling of bilirubin and drugs.

  2024cites this paper
• The Effects of Jabara Juice on the Intestinal Permeation of Fexofenadine.

  2023cites this paper
• Uptake Transporters at the Blood–Brain Barrier and Their Role in Brain Drug Disposition

  2023cites this paper
• Changes in Expression and Function of Placental and Intestinal P-gp and BCRP Transporters during Pregnancy

  2023cites this paper
• Effect of Chronic Hepatitis C on the Activity of the Membrane Transporters P‐gp and OATP1B1/BCRP on Patients With Different Stages of Hepatic Fibrosis

  2023cites this paper
• Fexofenadine Plasma Concentrations to Estimate Systemic Exposure in Healthy Adults Using a Limited Sampling Strategy with a Population Pharmacokinetic Approach

  2023cites this paper
• Maximizing the Oral Bioavailability of Poorly Water-Soluble Drugs Using Novel Oil-Like Materials in Lipid-Based Formulations.

  2021cites this paper
• Characterization of the Human Intestinal Drug Transport with Ussing Chamber System Incorporating Freshly Isolated Human Jejunum

  2020cites this paper
• Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug–Drug Interaction Studies

  2020cites this paper
• Application of genetically modified rodent models in drug discovery and development for translation of clinical ADME properties

  2020cites this paper
• Effect of Rumex Acetosa Extract, a Herbal Drug, on the Absorption of Fexofenadine

  2020cites this paper
• Chiral Discrimination of P-glycoprotein in Parturient Women: Effect of Fluoxetine on Maternal-Fetal Fexofenadine Pharmacokinetics

  2020cites this paper
• A Method of Analysis of the Functional Activity of P-Glycoprotein in the Blood–Brain Barrier

  2019cites this paper
• Discovery of Axelopran (TD-1211): A Peripherally Restricted μ-Opioid Receptor Antagonist.

  2019cites this paper
• Drug-Drug Interactions of P-gp Substrates Unrelated to CYP Metabolism.

  2019cites this paper
• Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR‐Mutated Non–Small Cell Lung Cancer

  2019cites this paper
• Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives

  2019cites this paper
• Enantioselective Drug Recognition by Drug Transporters

  2018influential citation
• How do oral insecticidal compounds cross the insect midgut epithelium?

  2018cites this paper
• Impact of ABCB1 genotype in Collies on the pharmacokinetics of R‐ and S‐fexofenadine

  2018cites this paper
• Dual targeting agents for Aβ plaque/P-glycoprotein and Aβ plaque/nicotinic acetylcholine α4β2* receptors—potential approaches to facilitate Aβ plaque removal in Alzheimer’s disease brain

  2018cites this paper
• An update on the clinical pharmacokinetics of fexofenadine enantiomers

  2018cites this paper
• Design and preparation of controlled floating gastroretentive delivery systems for enhanced fexofenadine hydrochloride oral bioavailability

  2018cites this paper
• Brain and the Drug Transporters

  2017cites this paper
• Understanding the Interplay Between Uptake and Efflux Transporters Within In Vitro Systems in Defining Hepatocellular Drug Concentrations.

  2017cites this paper
• Fexofenadine, a Putative In Vivo P‐glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients

  2017cites this paper
• Why Does the Intestine Lack Basolateral Efflux Transporters for Cationic Compounds? A Provocative Hypothesis.

  2016cites this paper
• Evaluating the role of intestinal transporters in fruit juice-drug interactions

  2016influential citation
• Quantitative Targeted Absolute Proteomics for 28 Transporters in Brush-Border and Basolateral Membrane Fractions of Rat Kidney.

  2016cites this paper
• Comment on “Sweat but no gain”: Inhibiting proliferation of multidrug resistant cancer cells with “Ersatzdroges”

  2015cites this paper
• [Determinants of the stereoselective pharmacokinetics of fexofenadine].

  2015cites this paper
• Case Studies of Non‐CNS Drugs to Minimize Brain Penetration—Nonsedative Antihistamines

  2015cites this paper
• Role of drug transporters: an overview based on knockout animal model studies

  2015cites this paper
• Restricting CNS penetration of drugs to minimise adverse events: role of drug transporters.

  2014cites this paper
• Various Drug-Transporters Related to the Fexofenadine Enantiomers Pharmacokinetics

  2014influential citation
• Investigations into rat hepatobiliary drug clearance pathways in early drug discovery.

  2014cites this paper
• Development of a Physiologically-Based Pharmacokinetic Model of the Rat Central Nervous System

  2014cites this paper
• In Vivo Alterations in Drug Metabolism and Transport Pathways in Patients with Chronic Kidney Diseases

  2014cites this paper
• Analysis of the pharmacokinetic boosting effects of ritonavir on oral bioavailability of drugs in mice.

  2013cites this paper
• DMD050062 1004..1011

  2013cites this paper
• Effect of Coadministration of Single and Multiple Doses of Rifampicin on the Pharmacokinetics of Fexofenadine Enantiomers in Healthy Subjects

  2013cites this paper
• Comparison of in vitro-in vivo extrapolation of biliary clearance using an empirical scaling factor versus transport-based scaling factors in sandwich-cultured rat hepatocytes.

  2013cites this paper
• Enantioselective uptake of fexofenadine by Caco‐2 cells as model intestinal epithelial cells

  2013cites this paper
• A Modified Grapefruit Juice Eliminates Two Compound Classes as Major Mediators of the Grapefruit Juice–Fexofenadine Interaction: An In Vitro–In Vivo “Connect”

  2013cites this paper
• Species Differences in Biliary Clearance and Possible Relevance of Hepatic Uptake and Efflux Transporters Involvement

  2013cites this paper
• In Vitro–In Vivo Correlation for Low-Clearance Compounds Using Hepatocyte Relay Method

  2013cites this paper
• Species Difference in the Mechanism of Nonlinear Pharmacokinetics of E2074, a Novel Sodium Channel Inhibitor, in Rats, Dogs, and Monkeys

  2013cites this paper
• Drug transporters in drug efficacy and toxicity.

  2012cites this paper
• Les répercussions de l’insuffisance rénale chronique sur le transport des médicaments

  2012cites this paper
• Carbamazepine differentially affects the pharmacokinetics of fexofenadine enantiomers.

  2012cites this paper
• Pharmacokinetic interactions of clopidogrel with quercetin, telmisartan, and cyclosporine A in rats and dogs

  2012influential citation
• The role of brain and intestinal efflux transporters in disposition of central nervous system drugs

  2012cites this paper
• Animal Models for Studying Drug Metabolizing Enzymes and Transporters

  2012cites this paper
• Current Understanding of Drug Disposition in Kidney Disease

  2012cites this paper
• Pharmacokinetic interactions of clopidogrel with quercetin, telmisartan, and cyclosporine A in rats and dogs

  2012cites this paper
• Blood-brain barrier in vitro models as tools in drug discovery: assessment of the transport ranking of antihistaminic drugs.

  2012cites this paper
• Vectorial transport of fexofenadine across Caco-2 cells: involvement of apical uptake and basolateral efflux transporters.

  2011cites this paper
• Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability.

  2010cites this paper
• Histamine, histamine receptors and antihistamines: new concepts.

  2010cites this paper
• Microdosing: current and the future.

  2010cites this paper
• Evaluation of In Vivo P-Glycoprotein Phenotyping Probes

  2010cites this paper
• Regional absorption of fexofenadine in rat intestine.

  2010cites this paper
• Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs.

  2010cites this paper
• Microdose study of a P‐glycoprotein substrate, fexofenadine, using a non‐radioisotope‐labelled drug and LC/MS/MS

  2010cites this paper
• Xenobiotic, Bile Acid, and Cholesterol Transporters: Function and Regulation

  2010influential citation
• Overcoming drug resistance by regulating nuclear receptors.

  2010cites this paper
• Pharmacokinetics of fexofenadine following LPS administration to rats

  2010influential citation
• Effect of piperine, a major component of black pepper, on the intestinal absorption of fexofenadine and its implication on food-drug interaction.

  2010cites this paper
• Oral bioavailability of P-glycoprotein substrate drugs do not differ between ABCB1-1Δ and ABCB1 wild type dogs.

  2010cites this paper
• The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber

  2010cites this paper
• Relevance of Two Genes in the Multidrug Resistance of Hepatocellular Carcinoma: In Vivo and Clinical Studies

  2010cites this paper
• Synergism of hydroxyapatite nanoparticles and recombinant mutant human tumour necrosis factor‐α in chemotherapy of multidrug‐resistant hepatocellular carcinoma

  2010cites this paper
• Histamina, receptores de histamina e anti-histamínicos: novos conceitos

  2010cites this paper
• ABCC2/Abcc2: a multispecific transporter with dominant excretory functions

  2010cites this paper
• Pharmacokinetic drug interaction between fexofenadine and fluvastatin mediated by organic anion-transporting polypeptides in rats.

  2009cites this paper
• In vitro-in vivo correlation in P-glycoprotein mediated transport in intestinal absorption.

  2009cites this paper
• Chapter 11. Hepatic Transport

  2009cites this paper
• The role of P-glycoprotein in intestinal transport versus the BBB transport of tetraphenylphosphonium.

  2009cites this paper
• ESRD impairs nonrenal clearance of fexofenadine but not midazolam.

  2009cites this paper
• The Inhibition of Human Multidrug and Toxin Extrusion 1 Is Involved in the Drug-Drug Interaction Caused by Cimetidine

  2009cites this paper
• Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders

  2009cites this paper
• Integration of Preclinical and Clinical Data with Pharmacokinetic Modeling and Simulation to Evaluate Fexofenadine as a Probe for Hepatobiliary Transport Function

  2009influential citation
• Drug metabolism and pharmacokinetics

  2009cites this paper
• Liver transporters in hepatic drug disposition: an update.

  2009cites this paper
• Assessment of Blood–Brain Barrier Permeability Using the In Situ Mouse Brain Perfusion Technique

  2009cites this paper
• N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a "chemical knock-out equivalent" to assess the impact of efflux transporters on oral drug absorption in the rat.

  2009cites this paper
• Impact of Basolateral Mrp3 (Abcc3) and Mrp4 (Abcc4) on the Hepatobiliary Disposition of Fexofenadine in Perfused Mouse Livers

  2009influential citation
• Fexofenadine Brain Exposure and the Influence of Blood-Brain Barrier P-Glycoprotein After Fexofenadine and Terfenadine Administration

  2009influential citation
• Blood−brain barrier transporters and response to CNS-active drugs

  2009cites this paper
• Drug transporters: Gatekeepers controlling access of xenobiotics to the cellular interior

  2009cites this paper
• Characterization of Anti-Inflammatory Properties and Evidence for No Sedation Liability for the Novel Antihistamine SUN-1334H

  2009cites this paper
• Long-term effects of Panax ginseng on disposition of fexofenadine in rats in vivo.

  2009cites this paper
• The inhibition of human multidrug and toxin extrusion 1 (hMATE1) is involved in the drug-drug interaction caused by cimetidine

  2008cites this paper
• Relative contribution of absorptive and secretory transporters to the intestinal absorption of fexofenadine in rats.

  2008cites this paper
• Validation of the use of nonnaive surgically catheterized rats for pharmacokinetics studies.

  2008cites this paper
• Physicochemical, pharmacological and pharmacokinetic properties of the zwitterionic antihistamines cetirizine and levocetirizine.

  2008cites this paper
• Analysis of disease-dependent sedative profiles of H(1)-antihistamines by large-scale surveillance using the visual analog scale.

  2008cites this paper
• Modest Effect of Impaired P-glycoprotein on the Plasma Concentrations of Fexofenadine, Quinidine, and Loperamide following Oral Administration in Collies

  2008cites this paper
• Involvement of Multiple Efflux Transporters in Hepatic Disposition of Fexofenadine

  2008influential citation